Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisotumab Vedotin in Advanced Solid Tumors
NCT02001623Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Nov 2013
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of tisotumab vedotin in ovarian cancer, Cervical Cancer (CC), endometrial cancer (EC), bladder cancer, castration-resistant prostate cancer (CRPC), sponsored by Seagen Inc.. Started Nov 2013; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
ovarian cancerCervical Cancer (CC)endometrial cancer (EC)bladder cancercastration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02001623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02001623.